DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
8.42
-0.08 (-0.94%)
At close: Feb 20, 2026, 4:00 PM EST
8.55
+0.13 (1.54%)
After-hours: Feb 20, 2026, 5:47 PM EST
DiaMedica Therapeutics Employees
As of December 31, 2024, DiaMedica Therapeutics had 28 total employees, including 27 full-time and 1 part-time employees. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,140,214
Market Cap
451.13M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | 11 | 2 | 22.22% | 10 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| 4D Molecular Therapeutics | 227 |
| Kyverna Therapeutics | 129 |
| Solid Biosciences | 100 |
| Invivyd | 100 |
| Verastem | 78 |
| Assembly Biosciences | 73 |
| Lexeo Therapeutics | 61 |
| PepGen | 57 |
DMAC News
- 5 weeks ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire
- 3 months ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights - Business Wire
- 3 months ago - DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 3 months ago - DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 - Business Wire
- 5 months ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 6 months ago - DiaMedica Therapeutics to Participate in Upcoming Investor Conferences - Business Wire